Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

This study has been withdrawn prior to enrollment.
(Gemcitabine is not the first choice for most pancreatic cancer patients nowdays)
Sponsor:
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital
ClinicalTrials.gov Identifier:
NCT01598584
First received: May 5, 2012
Last updated: September 24, 2015
Last verified: December 2012
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)